{"filing":{"accession_number":"0001104659-26-103548","cik":"0001561921","ticker":"TELA","company_name":"TELA Bio, Inc.","form":"8-K","filing_date":"2026-08-31","report_date":"2026-08-28","primary_document":"tm2624299d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926103548/tm2624299d1_8k.htm"},"events":[{"id":30481,"run_id":27932,"accession_number":"0001104659-26-103548","anchor_item_number":"2.05","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"TELA Bio announced a Board-approved workforce reduction plan reducing headcount by approximately 20% (from 201 to 160 employees) as part of a $17 million annual cost reduction initiative, with expected one-time restructuring charges of $1.5 million in severance and employee-related costs to be incurred in Q3 2026.","company_name":"TELA Bio, Inc.","ticker":"TELA","filing_date":"2026-08-31","form":"8-K","submitted_at":null,"items":[{"id":33085,"accession_number":"0001104659-26-103548","item_number":"2.05","item_title":null,"event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a Board-approved workforce reduction plan reducing headcount by approximately 20% (from 201 to 160 employees) with expected charges of $1.5 million in severance and employee-related costs to be incurred in Q3 2026. This is a classic Item 2.05 disclosure of exit or disposal activities with associated restructuring charges, designed to reduce operating expenses and preserve capital. The supplemental press release confirms this is part of a broader $17 million annual cost reduction initiative.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:06:50.966617+00:00","company_name":"","ticker":null,"filing_date":""},{"id":33087,"accession_number":"0001104659-26-103548","item_number":"7.01","item_title":null,"event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on a strategic cost reduction initiative involving a targeted headcount reduction of approximately 20% and $17.0 million in annual operating expense reductions, with a one-time restructuring charge of $1.5 million anticipated in Q3 2026. While the filing also mentions the departure of the COO/CFO Roberto Cuca, the principal focus of the press release is the broader workforce reduction and operational restructuring program, making this a workforce_reduction event rather than exec_departure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:06:50.966617+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":30482,"run_id":27932,"accession_number":"0001104659-26-103548","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Roberto Cuca stepped down as Chief Financial Officer, Chief Operating Officer, and Corporate Secretary effective August 31, 2026, treated as a termination without cause. Heather Getz was appointed as principal financial officer to succeed him.","company_name":"TELA Bio, Inc.","ticker":"TELA","filing_date":"2026-08-31","form":"8-K","submitted_at":null,"items":[{"id":33086,"accession_number":"0001104659-26-103548","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Roberto Cuca stepped down as Chief Financial Officer, Chief Operating Officer, and Corporate Secretary effective August 31, 2026, treated as a termination without cause. While Heather Getz was appointed as principal financial officer, the primary disclosed action centers on Cuca's departure from multiple senior leadership roles. The filing also discloses a concurrent $17 million cost reduction initiative with 20% headcount reduction and $1.5 million restructuring charge, but the Item 5.02 focus is on the executive departure itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:06:50.966617+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33085,"accession_number":"0001104659-26-103548","item_number":"2.05","item_title":null,"event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a Board-approved workforce reduction plan reducing headcount by approximately 20% (from 201 to 160 employees) with expected charges of $1.5 million in severance and employee-related costs to be incurred in Q3 2026. This is a classic Item 2.05 disclosure of exit or disposal activities with associated restructuring charges, designed to reduce operating expenses and preserve capital. The supplemental press release confirms this is part of a broader $17 million annual cost reduction initiative.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:06:50.966617+00:00","company_name":"TELA Bio, Inc.","ticker":"TELA","filing_date":"2026-08-31"},{"id":33086,"accession_number":"0001104659-26-103548","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Roberto Cuca stepped down as Chief Financial Officer, Chief Operating Officer, and Corporate Secretary effective August 31, 2026, treated as a termination without cause. While Heather Getz was appointed as principal financial officer, the primary disclosed action centers on Cuca's departure from multiple senior leadership roles. The filing also discloses a concurrent $17 million cost reduction initiative with 20% headcount reduction and $1.5 million restructuring charge, but the Item 5.02 focus is on the executive departure itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:06:50.966617+00:00","company_name":"TELA Bio, Inc.","ticker":"TELA","filing_date":"2026-08-31"},{"id":33087,"accession_number":"0001104659-26-103548","item_number":"7.01","item_title":null,"event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on a strategic cost reduction initiative involving a targeted headcount reduction of approximately 20% and $17.0 million in annual operating expense reductions, with a one-time restructuring charge of $1.5 million anticipated in Q3 2026. While the filing also mentions the departure of the COO/CFO Roberto Cuca, the principal focus of the press release is the broader workforce reduction and operational restructuring program, making this a workforce_reduction event rather than exec_departure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:06:50.966617+00:00","company_name":"TELA Bio, Inc.","ticker":"TELA","filing_date":"2026-08-31"}]}